Get the Stockscreener App
4.17
2.57%
-0.11
After Hours:
4.17
Cytek Biosciences Inc Stock (CTKB) Latest News
Cytek Biosciences stock hits 52-week low at $4.19 amid market challenges - Investing.com India
Cytek Biosciences, Inc. (CTKB): Why Are Hedge Funds Bullish On This Cash-Rich Penny Stock? - Insider Monkey
12 Cash-Rich Penny Stocks To Buy According To Hedge Funds - Insider Monkey
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2024 Earnings Call Transcript - MSN
Cytek Biosciences (CTKB) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Bought by Principal Financial Group Inc. - Defense World
Cytek Biosciences (NASDAQ:CTKB) Price Target Cut to $8.00 by Analysts at Piper Sandler - Defense World
Cytek Biosciences Reports Mixed Earnings Amid Growth and Challenges - TipRanks
Cytek Biosciences (NASDAQ:CTKB) Hits New 1-Year Low – Here’s Why - Defense World
Cytek Biosciences stock hits 52-week low at $4.6 amid market challenges - Investing.com Australia
Is There An Opportunity With Cytek Biosciences, Inc.'s (NASDAQ:CTKB) 22% Undervaluation? - Yahoo Finance
Cytek Biosciences (NASDAQ:CTKB) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Cytek Biosciences stock hits 52-week low at $4.6 amid market challenges By Investing.com - Investing.com South Africa
Cytek Biosciences, Inc. SEC 10-K Report - TradingView
Cytek Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cytek Biosciences Reports Growth and Strategic Expansion - TipRanks
Cytek Biosciences earnings beat by $0.01, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Cytek Biosciences Q4 2024 results miss forecasts By Investing.com - Investing.com South Africa
Cytek Biosciences, Inc. (CTKB) Tops Q4 Earnings Estimates - Yahoo Finance
Earnings call transcript: Cytek Biosciences Q4 2024 results miss forecasts - Investing.com
Cytek Biosciences reports Q4 revenue $57.48M, consensus $59.38M - TipRanks
Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook - GlobeNewswire
Cytek's Earnings Show Profitability Surge: Net Loss Halved While Revenue Climbs Just 4% - StockTitan
Cytek Biosciences (CTKB) to Release Quarterly Earnings on Thursday - MarketBeat
(CTKB) Proactive Strategies - Stock Traders Daily
Cytek Biosciences, Inc. (NASDAQ:CTKB) Short Interest Update - MarketBeat
Cytek Biosciences (CTKB) Projected to Post Quarterly Earnings on Thursday - Defense World
Cytek Biosciences (NASDAQ:CTKB) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Prenetics Global (NASDAQ:PRE) and Cytek Biosciences (NASDAQ:CTKB) Head to Head Analysis - Defense World
Cytek Biosciences to Announce Q4 and Full Year 2024 Financial Results on February 27, 2025 - Nasdaq
Cytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 - GlobeNewswire
Cytek Biosciences Earnings Alert: Key Q4 and Full Year 2024 Results Coming February 27 - StockTitan
Cytek Biosciences, Inc. (NASDAQ:CTKB) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St
Cytek Biosciences (NASDAQ:CTKB) Sees Unusually-High Trading Volume – Here’s What Happened - Defense World
Keeping an Eye on Cytek BioSciences Inc (CTKB) After Insider Trading Activity - Knox Daily
Cytek Biosciences (NASDAQ:CTKB) Trading Down 4%Should You Sell? - MarketBeat
Cytek Biosciences (NASDAQ:CTKB) Shares Up 5%What's Next? - MarketBeat
Cytek Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire
Strategic Investor Access: Cytek Sets Ambitious 4-Conference Roadshow for Early 2025 - StockTitan
Pacer Advisors Inc. Buys Shares of 30,155 Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences (NASDAQ:CTKB) Trading Down 4% – Should You Sell? - Armenian Reporter
Market Insights: Cytek BioSciences Inc (CTKB)’s Notable Gain of 4.66, Closing at 5.39 - The Dwinnex
Cytek Biosciences (NASDAQ:CTKB) Shares Gap DownHere's Why - MarketBeat
Cytek Biosciences price target raised to $5.25 from $4.50 at Goldman Sachs - MSN
Cytek Biosciences (NASDAQ:CTKB) Cut to Sell at The Goldman Sachs Group - Defense World
3.08%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):